 |
|
|
|||||
Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at ASCO 2025. The stock rose 2.2% on Monday, with analysts maintaining a 'Buy' rating.
Category:
News and Media
DCM Shriram's shares surged by 10.5% following a robust Q4 FY25 performance, with net profit soaring 51.9% to Rs 178.9 crore. Revenue climbed 19.9% to Rs 2,876.7 crore, driven by strong segment results and improved EBITDA margins of 14.1%. The board has proposed a final dividend of Rs 3.40 per share.
Category:
News and Media
From the tactical success of the Elever FactorShields Fund, which delivered 20% returns in FY25, to sharp views on the US-led macro shifts and sector rotation strategies, Aggarwal outlines how investors can align portfolios for stability and long-term alpha. Edited Excerpts
Category:
News and Media
All news |
||||||||||||||||||
|
||||||||||||||||||